BNP和NT-proBNP 分不清?一文轻松掌握!

2022-07-11 检验医学 检验医学

一文全懂~

图片
图片
图片
图片
图片

 

参考文献:

[1]李琦,陈照生,尚晓泓.B型钠尿肽的生物学特性及临床研究进展[J].国际检验医学杂志,2010,31(10):1135-1137.

[2]张国华,胡韵,史晓敏,徐国宾,夏铁安.B型钠尿肽的生物学特性及其在心脏病学中的临床应用进展[J].中华检验医学杂志,2004(04):57-60.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1289353, encodeId=6487128935326, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290372, encodeId=673612903e27a, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602437, encodeId=4bfa160243e7e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231938, encodeId=78c61231938eb, content=这次明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5e1771308, createdName=ms8547501655805392, createdTime=Tue Jul 12 08:30:20 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-13 huiwelcome
  2. [GetPortalCommentsPageByObjectIdResponse(id=1289353, encodeId=6487128935326, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290372, encodeId=673612903e27a, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602437, encodeId=4bfa160243e7e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231938, encodeId=78c61231938eb, content=这次明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5e1771308, createdName=ms8547501655805392, createdTime=Tue Jul 12 08:30:20 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-13 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=1289353, encodeId=6487128935326, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290372, encodeId=673612903e27a, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602437, encodeId=4bfa160243e7e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231938, encodeId=78c61231938eb, content=这次明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5e1771308, createdName=ms8547501655805392, createdTime=Tue Jul 12 08:30:20 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-13 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1289353, encodeId=6487128935326, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290372, encodeId=673612903e27a, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602437, encodeId=4bfa160243e7e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jul 13 10:25:29 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231938, encodeId=78c61231938eb, content=这次明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5e1771308, createdName=ms8547501655805392, createdTime=Tue Jul 12 08:30:20 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-12 ms8547501655805392

    这次明白了

    0

相关资讯

JACC:NT-proBNP和 “新四联”恩格列净在心衰预后中的作用

较高的基线NT-proBNP浓度与较大的心力衰竭或肾脏不良结局风险有关,但无论基线NT-proBNP浓度如何,恩格列净都会降低上述风险。

JAHA:NT-proBNP作为COVID-19患者严重程度和结局的生物标志物

因COVID-19入院时NT-proBNP水平升高与伴有和不伴有心力衰竭患者的院内死亡率和其他并发症的风险增加相关。

JAMA子刊:无症状主动脉瓣狭窄需年度复查这一指标,或能准确预测临床结局!

在无症状的非严重AS患者中,随访1年时NT-proBNP浓度正常与低AVE和全因死亡率有关。

JACC:NT-proBNP水平越高,心衰患者预后越差!

基线NT-proBNP水平越高,提示心力衰竭患者发生不良心衰或肾脏结局的风险越高

BNP和NT-proBNP分不清?一文轻松掌握!

我是谁,从哪来,到哪去?哲学终极三问—BNP和NT-proBNP,一文读懂。